The Annual General Meeting of Diamyd Medical AB (publ) was held on November 24, 2016.

The Company's income statement and balance sheet were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2015/2016 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2015/2016 fiscal year.

Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller and Maria-Teresa Essen-Möller were re-elected to the Board.

The Annual General Meeting approved the proposed remuneration to Board members and the Chairman of the Board.

The Annual General Meeting resolved to re-elect the auditing company BDO until the end of the Annual General Meeting 2017. Principal auditor is the authorized public accountant Johan Pharmanson.

The Annual General Meeting resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting to issue shares and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd^®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Six clinical studies are ongoing with Diamyd^®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB (former Cellaviva AB). Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: www.diamyd.com